CONMED CORPORATION (CNMD) Spending and interest coverage
- R&D / revenue · 12 months: Value 4.42%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.48%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value 3.69×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 4.42% | Research and development expense / revenue. Period ending 2026-06-30. $60.63M ÷ $1.37B × 100 ≈ 4.42% |
| Stock-based compensation / revenue · 12 months | 1.48% | Share-based compensation / revenue. Period ending 2026-06-30. $20.29M ÷ $1.37B × 100 ≈ 1.48% |
| Interest coverage · 12 months | 3.69× | Operating income ÷ reported interest expense. $110.32M ÷ $29.92M ≈ 3.69× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 60.63M USD | Research and Development Expense |
| Revenue | 1.37B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 20.29M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 110.32M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 29.92M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $60.63M | $1.37B | $20.29M | $110.32M | $29.92M | 4.42% | 1.48% | 3.69× | Reported |
| 2025-12-31 | $55.88M | $1.37B | $28.32M | $102.62M | $31.09M | 4.07% | 2.06% | 3.30× | Reported |
| 2025-09-30 | $54.16M | $1.35B | $29.57M | $118.50M | $32.57M | 4.02% | 2.19% | 3.64× | Reported |
| 2025-06-30 | $53.82M | $1.33B | $31.11M | $172.32M | $34.22M | 4.06% | 2.35% | 5.04× | Reported |
| 2025-03-31 | $53.78M | $1.32B | $33.18M | $181.27M | $35.99M | 4.09% | 2.52% | 5.04× | Reported |
| 2024-12-31 | $54.43M | $1.31B | $25.56M | $200.33M | $37.30M | 4.16% | 1.96% | 5.37× | Reported |
| 2024-09-30 | $55.28M | $1.29B | $25.26M | $198.01M | $37.94M | 4.29% | 1.96% | 5.22× | Reported |
| 2024-06-30 | $54.18M | $1.28B | $25.32M | $162.61M | $38.71M | 4.25% | 1.98% | 4.20× | Reported |
| 2024-03-31 | $53.66M | $1.26B | $24.77M | $142.92M | $39.11M | 4.25% | 1.96% | 3.65× | Reported |
| 2023-12-31 | $52.60M | $1.24B | $24.26M | $120.60M | $39.77M | 4.23% | 1.95% | 3.03× | Reported |
| 2023-09-30 | $50.79M | $1.17B | $24.09M | $69.32M | $39.71M | 4.35% | 2.06% | 1.75× | Reported |
| 2023-06-30 | $51.10M | $1.14B | $23.66M | $63.27M | $38.23M | 4.49% | 2.08% | 1.65× | Reported |
| 2023-03-31 | $49.02M | $1.10B | $22.99M | $60.31M | $34.16M | 4.46% | 2.09% | 1.77× | Reported |
| 2022-12-31 | $47.15M | $1.05B | $21.73M | $70.05M | $28.91M | 4.51% | 2.08% | 2.42× | Reported |
| 2022-09-30 | $46.29M | $1.07B | $20.30M | $108.36M | $27.03M | 4.33% | 1.90% | 4.01× | Reported |
| 2022-06-30 | $44.39M | $1.04B | $18.88M | $110.83M | $26.64M | 4.26% | 1.81% | 4.16× | Reported |
| 2022-03-31 | $44.21M | $1.02B | $17.41M | $112.08M | $30.13M | 4.33% | 1.71% | 3.72× | Reported |
| 2021-12-31 | $43.56M | $1.01B | $16.34M | $109.72M | $35.48M | 4.31% | 1.62% | 3.09× | Reported |
| 2021-09-30 | $43.92M | $989.49M | $14.99M | $97.20M | $39.03M | 4.44% | 1.52% | 2.49× | Reported |
| 2021-06-30 | $43.00M | $978.50M | $14.20M | $99.87M | $42.83M | 4.39% | 1.45% | 2.33× | Reported |
| 2021-03-31 | $40.38M | $881.13M | $13.47M | $52.92M | $44.81M | 4.58% | 1.53% | 1.18× | Reported |
| 2020-12-31 | $40.47M | $862.46M | $13.11M | $46.01M | $44.05M | 4.69% | 1.52% | 1.04× | Reported |
| 2020-09-30 | $40.85M | $874.50M | $13.08M | $49.19M | $43.26M | 4.67% | 1.50% | 1.14× | Reported |
| 2020-06-30 | $41.90M | $870.25M | $12.55M | $40.74M | $42.49M | 4.81% | 1.44% | 0.96× | Reported |
| 2020-03-31 | $45.01M | $950.73M | $12.11M | $80.65M | $42.92M | 4.73% | 1.27% | 1.88× | Reported |
| 2019-12-31 | $45.46M | $955.10M | $11.78M | $79.11M | $42.70M | 4.76% | 1.23% | 1.85× | Reported |
| 2019-09-30 | $43.74M | $932.67M | $11.39M | $77.06M | $37.91M | 4.69% | 1.22% | 2.03× | Reported |
| 2019-06-30 | $46.87M | $901.39M | $10.89M | $67.64M | $31.95M | 5.20% | 1.21% | 2.12× | Reported |
| 2019-03-31 | $45.05M | $875.95M | $10.44M | $65.66M | $25.20M | 5.14% | 1.19% | 2.61× | Reported |
| 2018-12-31 | $42.19M | $859.63M | $10.04M | $71.31M | $20.65M | 4.91% | 1.17% | 3.45× | Reported |
| 2018-09-30 | $40.20M | $839.75M | $9.60M | $68.66M | $20.00M | 4.79% | 1.14% | 3.43× | Reported |
| 2018-06-30 | $34.34M | $827.56M | $9.20M | $70.61M | $19.59M | 4.15% | 1.11% | 3.60× | Reported |
| 2018-03-31 | $32.40M | $811.89M | $8.82M | $66.71M | $18.90M | 3.99% | 1.09% | 3.53× | Reported |
| 2017-12-31 | $32.31M | $796.39M | $8.47M | $46.94M | $18.20M | 4.06% | 1.06% | 2.58× | Reported |
| 2017-09-30 | $31.56M | $777.93M | $8.21M | $36.37M | $17.23M | 4.06% | 1.06% | 2.11× | Reported |
| 2017-06-30 | $31.65M | $772.61M | $8.01M | $36.74M | $16.29M | 4.10% | 1.04% | 2.26× | Reported |
| 2017-03-31 | $31.61M | $768.89M | $7.84M | $31.64M | $15.65M | 4.11% | 1.02% | 2.02× | Reported |
| 2016-12-31 | $32.25M | $763.52M | $8.38M | $37.68M | $15.36M | 4.22% | 1.10% | 2.45× | Reported |
| 2016-09-30 | $31.36M | $750.44M | $8.44M | $38.04M | $13.03M | 4.18% | 1.13% | 2.92× | Reported |
| 2016-06-30 | $29.66M | $734.84M | $8.30M | $39.03M | $10.67M | 4.04% | 1.13% | 3.66× | Reported |
| 2016-03-31 | $29.15M | $722.43M | $8.13M | $43.76M | $8.40M | 4.04% | 1.13% | 5.21× | Reported |
| 2015-12-31 | $27.44M | $719.17M | $7.50M | $51.17M | $6.03M | 3.81% | 1.04% | 8.49× | Reported |
| 2015-09-30 | $27.80M | $723.15M | $7.20M | $55.30M | $5.99M | 3.84% | 1.00% | 9.23× | Reported |
| 2015-06-30 | $28.06M | $728.93M | $10.59M | $42.91M | $6.03M | 3.85% | 1.45% | 7.12× | Reported |
| 2015-03-31 | $27.41M | $736.05M | $10.00M | $46.43M | $6.11M | 3.72% | 1.36% | 7.60× | Reported |
| 2014-12-31 | $27.78M | $740.05M | $9.33M | $52.79M | $6.11M | 3.75% | 1.26% | 8.64× | Reported |
| 2014-09-30 | $27.11M | $748.49M | $9.18M | $51.88M | $6.05M | 3.62% | 1.23% | 8.57× | Reported |
| 2014-06-30 | $27.31M | $752.79M | $5.62M | $58.23M | $5.90M | 3.63% | 0.75% | 9.88× | Reported |
| 2014-03-31 | $27.05M | $757.63M | $5.63M | $57.95M | $5.71M | 3.57% | 0.74% | 10.15× | Reported |
| 2013-12-31 | $25.83M | $762.70M | $5.59M | $56.51M | $5.61M | 3.39% | 0.73% | 10.07× | Reported |
| 2013-09-30 | $26.24M | $760.51M | $5.64M | $57.34M | $5.53M | 3.45% | 0.74% | 10.37× | Reported |
| 2013-06-30 | $26.21M | $763.14M | $5.58M | $62.65M | $5.49M | 3.43% | 0.73% | 11.41× | Reported |
| 2013-03-31 | $26.81M | $759.84M | $5.62M | $64.06M | $5.66M | 3.53% | 0.74% | 11.32× | Reported |
| 2012-12-31 | $28.21M | $767.14M | $5.65M | $65.21M | $5.73M | 3.68% | 0.74% | 11.38× | Reported |
| 2012-09-30 | $28.52M | $751.47M | $5.64M | $6.57M | $5.83M | 3.79% | 0.75% | 1.13× | Reported |
| 2012-06-30 | $28.46M | $742.40M | $5.58M | $8.39M | $6.15M | 3.83% | 0.75% | 1.36× | Reported |
| 2012-03-31 | $28.07M | $735.94M | $5.40M | $8.03M | $6.31M | 3.81% | 0.73% | 1.27× | Reported |
| 2011-12-31 | $28.65M | $725.08M | $5.24M | $8.27M | $6.68M | 3.95% | 0.72% | 1.24× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | $720.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $29.65M | $713.72M | $4.22M | $57.09M | $7.11M | 4.15% | 0.59% | 8.03× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $31.84M | $694.74M | $4.31M | $28.27M | $7.09M | 4.58% | 0.62% | 3.99× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B |